GlassScriptPhysician profile
Barry R Fabriziani
NPI 1700840782
$3,077.51
in general payments reported to CMS, 2019-2025
23 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $59.44 · 2021: $261 · 2022: $318 · 2023: $467 · 2024: $582 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $791.45 | 2021-2025 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Bausch & Lomb Americas INC. | $764.38 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Alcon Vision LLC | $287.05 | 2021-2025 | Precision 1, Precision7, Rocklatan |
| Abbvie INC. | $256.47 | 2022-2023 | |
| Dompe US, INC. | $168.68 | 2022-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $162.52 | 2019-2021 | |
| Allergan, INC. | $142.57 | 2019-2021 | |
| Astellas Pharma US INC | $85.38 | 2024 | Izervay |
| Biotissue Holdings INC. | $59.47 | 2025 | |
| Mallinckrodt Hospital Products INC. | $57.60 | 2024-2025 | Acthar |
| Eyevance Pharmaceuticals LLC | $48.36 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $35.81 | 2023-2024 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $30.55 | 2024 | Xdemvy |
| Maculogix, INC. | $27.16 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $20.41 | 2025 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $20.24 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $19.15 | 2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $18.85 | 2025 | Tecnis Iol |
| Amgen INC. | $18.25 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $15.16 | 2024 | Tyrvaya |
| Visioneering Technologies, INC. | $14.96 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Fabriziani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.